

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims:

1. (Amended) A self-assembled biomolecular structure comprising affinity modules, said affinity modules each having at least two affinity domains which may be the same or different, at least one affinity domain within each affinity module having specific and exclusive affinity for an affinity domain within another affinity module, said affinity modules being capable of biospecific interaction to form an assembled structure.
2. (Original) A structure as claimed in claim 1 wherein at least one of the affinity domains comprises a protein molecule.
3. (Original) A structure as claimed in claim 2 wherein each affinity module comprises at least one affinity domain which comprises a protein molecule.

4. (Original) A structure as claimed in claim 3 wherein all affinity domains comprise a protein molecule.

5. (Previously Presented) A structure as claimed in claim 1 which comprises at least two different types of affinity module.

6. (Previously Presented) A structure as claimed in claim 1 which comprises at least 4 different types of affinity domain.

7. (Previously Presented) A structure as claimed in claim 1 which comprises at least two pairs of affinity domains, each of said pairs having specific and exclusive affinity for each other.

8. (Previously Presented) A structure as claimed in claim 1 wherein one or more of the affinity domains has been selected from a molecular library.

9. (Previously Presented) A structure as claimed in claim 1 which comprises at least one affinity module which has two or more different affinity domains.

10. (Currently Amended) A structure as claimed in claim 1 which comprises at least one affinity module which has two or more ~~functionally equivalent affinity domains~~ capable of binding to the same binding partner and at least one affinity module which has two or more different affinity domains.

11. (Currently Amended) A structure as claimed in claim 1 wherein one or more of the affinity domains ~~is or is derived from a~~ comprises a modified or unmodified domain of a naturally occurring bacterial receptor.

12. (Original) A structure as claimed in claim 11 wherein said bacterial receptor is *Staphylococcal* protein A (SPA).

13. (Currently Amended) A structure as claimed in claim 12 wherein the affinity domain ~~is derived from~~ comprises a modified B domain of SPA.

Claims 14.-16. (Canceled)

17. (Original) A proteinaceous affinity module which comprises two or more proteinaceous affinity domains which may be the same or different, each affinity domain having specific and exclusive

affinity for a given binding partner, wherein at least one of the affinity domains has been selected from a molecular library.

18. (Original) An affinity module as claimed in claim 17 wherein one or more of the affinity domains is capable of specific and exclusive interaction with a bacterial receptor domain.

19. (Currently Amended) An affinity module as claimed in claim 17 wherein one of the affinity domains ~~is derived from a~~ comprises a modified bacterial receptor domain.

20. (Currently Amended) An isolated protein molecule ~~A protein molecule~~ having the amino acid sequence of SEQ ID NO:2 ~~SEQ ID No. 2~~ or variants thereof, said variants having modified domains wherein said modified domains have at least 80% of the binding affinity of SEQ ID NO:2 for SPA ~~having substantially the same affinity for SPA.~~

21. (Currently Amended) An isolated protein molecule ~~A protein molecular~~ having the amino acid sequence of SEQ ID NO:3 ~~SEQ ID No. 3~~ or variants thereof, said variants having modified domains wherein said modified domains have at least 80% of the binding

affinity of SEQ ID NO:3 for SPA ~~having substantially the same affinity for SPA.~~

22. (Canceled)

23. (Canceled)

24. (Previously Presented) A method of producing a self-assembled biomolecular structure, which comprises admixing affinity modules as defined in claim 1 in an environment which enables biospecific interaction between the affinity domains thereof.

25. (Previously Presented) A structure as claimed in claim 1 for use in therapy.

26. (Canceled)